通过协调代谢重编程和EMT介导的转移,PIK3C2B驱动肺癌的进展
Xinyue Chou1, Wenqian Li1, Yandong Li2
1South China University of Technology of Medicine, Guangzhou, 510006, China.
Biochemistry and biophysics reports
|December 9, 2025
概括
这项研究确定PIK3C2B是肺癌进展的关键驱动因素. 它促进转移和代谢变化,使其成为肺腺癌的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 肺癌是全球癌症死亡的主要原因之一.
- 转移和代谢适应是肺癌进展的关键驱动因素.
- 这些过程背后的特定分子机制尚未完全理解.
研究的目的:
- 确定肺癌转移和代谢适应的新型调节剂.
- 为了研究PIK3C2B (酸酸3-激酶催化子单元2β型) 在肺癌进展中的作用.
- 评估PIK3C2B作为潜在的预后标志物和治疗点.
主要方法:
- 对八个基因表达综合 (GEO) 数据集的整合性转录学分析.
- 对PIK3C2B表达与患者生存数据 (总体和无病生存) 的相关性分析.
- 患者瘤中PIK3C2B蛋白表达的免疫组织化学.
- 功能性研究涉及PIK3C2B淘汰和过度表达.
- 海马的代谢分析,以评估线粒体的氧化酸化和糖溶性流量.
主要成果:
- 确定PIK3C2B是一种与肺癌转移相关的持续失调的基因.
- 增加PIK3C2B表达与肺腺癌患者的总体和无病生存率降低显著相关.
- 过度表达PIK3C2B增强了癌细胞的增殖和迁移,而沉默则损害了这些过程.
- 皮克3C2B的表达与表皮细胞转移到介质酶细胞转移 (EMT) 调节器以及调节的线粒体和甘油性代谢有关.
结论:
- PIK3C2B作为一种双重功能上蛋白,通过EMT激活和代谢重编程促进肺癌的进展.
- PIK3C2B的预后意义和在代谢适应性中的作用表明它是一个有前途的治疗标.
- 准PIK3C2B可能会破坏肺癌转移并增强瘤的弹性.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K


